|
1
|
Mobasher M, Miller R, Janc J, Kwei L, Barker C, Mohammady A, Luciano G, Radeski D, Kim Y, Khodadoust M, Horwitz S. A PHASE 1/1B DOSE-ESCALATION TRIAL EVALUATING CPI-818, AN ORAL INTERLEUKIN-2-INDUCIBLE T-CELL KINASE INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY T-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.11_2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- M. Mobasher
- CMO; Corvus Pharmaceuticals; Burlingame United States
| | - R. Miller
- CEO; Corvus Pharmaceuticals; Burlingame United States
| | - J. Janc
- Pharmacology; Corvus Pharmaceuticals; Burlingame United States
| | - L. Kwei
- Biometrics; Corvus Pharmaceuticals; Burlingame United States
| | - C. Barker
- Clinical Development; Corvus Pharmaceuticals; Burlingame United States
| | - A. Mohammady
- Clinical Development; Corvus Pharmaceuticals; Burlingame United States
| | - G. Luciano
- Clinical Development; Corvus Pharmaceuticals; Burlingame United States
| | - D. Radeski
- Haematology Department; Linear Clinical Research; Nedlands Australia
| | - Y. Kim
- Department of Medicine; Stanford Cancer Institute; Stanford United States
| | - M. Khodadoust
- Department of Medicine; Stanford Cancer Institute; Stanford United States
| | - S. Horwitz
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| |
Collapse
|